Amgen Bispecific Antibody Blincyto Gets Green Light From Europe’s CHMP
This article was originally published in The Pink Sheet Daily
Executive Summary
The acute lymphoblastic leukemia therapy, already available in the US, was recommended for a conditional approval in Europe to speed early patient access.